Trk Receptors

TrkA/NGF-IN-1 is a potent inhibitor of the interaction between TrkA and nerve growth factor (NGF), with an IC50 of 21 nM as determined by the PathHunter assay. This peptide demonstrates significant analgesic activity in rodent models of incisional pain, making it a valuable tool for research on pain mechanisms and therapeutic interventions targeting the TrkA signaling pathway.

Trk-IN-2 is a potent pan-Trk kinase inhibitor, demonstrating an IC50 of 9 nM for the TrkA enzyme and a cell-based IC50 of 7 nM. This compound exhibits significant pharmacodynamic effects in rat models of inflammatory and neuropathic pain. Trk-IN-2 is valuable for research applications focused on the mechanisms and treatment of inflammatory pain and neuropathic pain conditions.

ITK/TRKA-IN-1 is a selective inhibitor targeting IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA), exhibiting an IC50 of 1.0 nM for ITK and achieving 96% inhibition of TRKA. This compound is valuable for investigating the roles of ITK and TRKA in immune responses and neurobiology. Its dual inhibitory action positions it as a significant tool for research in cancer immunotherapy and neurodegenerative disease studies, enabling the exploration of signaling pathways associated with these kinases.

PF-07245303 is an ITK/TRK inhibitor that effectively reduces the production of pro-inflammatory cytokines such as IL-4 and IFNγ. This compound inhibits the phosphorylation of PLCγ1 and disrupts nerve growth factor-induced basophil activation and TRKA phosphorylation. Additionally, PF-07245303 demonstrates a reduction in oxazolone-induced ear swelling in mouse models, making it a valuable tool for research into atopic dermatitis and related inflammatory conditions.